Success Metrics

Active Trials
2(67%)

Phase Distribution

Ph phase_4
2
67%

Phase Distribution

0

Early Stage

0

Mid Stage

2

Late Stage

Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

3

all time

Status Distribution
Active(3)

Detailed Status

Recruiting1
Active, not recruiting1
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
3
Active
2
Success Rate
N/A
Most Advanced
Phase 4

Trials by Phase

Phase 42 (100.0%)

Trials by Status

recruiting133%
active_not_recruiting133%
not_yet_recruiting133%

Recent Activity

2 active trials
Showing 3 of 3
not_yet_recruiting

Home Monitoring in eAMD Treatment

NCT07340372
active_not_recruitingphase_4

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

NCT07118670
recruitingphase_4

Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

NCT06683950

Clinical Trials (3)

Showing 3 of 3 trials
NCT07340372

Home Monitoring in eAMD Treatment

Not Yet Recruiting
NCT07118670Phase 4

High Dose Eylea for Proliferative Diabetic Retinopathy Outcomes

Active Not Recruiting
NCT06683950Phase 4

Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment

Recruiting

All 3 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
3